



POSTER PRESENTATION

Open Access

# Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression

D Archary<sup>1\*</sup>, R Rong<sup>2</sup>, ML Gordon<sup>1</sup>, S Boliar<sup>3</sup>, ES Gray<sup>4</sup>, A Dugast<sup>5</sup>, T Hermanus<sup>6</sup>, PJ Goulder<sup>7</sup>, HM Coovadia<sup>8</sup>, L Morris<sup>6</sup>, G Alter<sup>5</sup>, CA Derdeyn<sup>3</sup>, T Ndung'u<sup>1</sup>

From AIDS Vaccine 2012  
Boston, MA, USA. 9-12 September 2012

## Background

Development of an efficacious HIV-1 vaccine able to elicit the production of broadly neutralizing antibodies (nAbs), capable of retaining potent activity against a diverse panel of viral isolates remains a significant challenge. The evolutionary forces that shape envelope and ensuing nAb and non-neutralizing antibodies in HIV-1 subtype C are incompletely understood and these two parameters have been rarely studied concurrently.

## Methods

We characterized patterns of virus-specific nAbs and non-neutralizing antibodies in four slow progressors and four progressors with chronic HIV-1 subtype C infection, over a median of 21 months. Single cycle neutralization assays was performed. In addition, the binding affinities of HIV-specific immunoglobulins (IgGs) and the affinities of the IgGs to various Fcγ receptors (FcγRs) were assessed.

## Results

NAbs evolved significantly in progressors ( $p=0.003$ ) from study entry to study exit. NAb IC50 titers significantly correlated with amino acid lengths for V1-V2 ( $p=0.04$ ), C3-V5 ( $p=0.03$ ) and V1-V5 ( $p=0.04$ ). Both groups displayed preferential heterologous activity against the subtype C panel. Both groups displayed preferential heterologous activity against the subtype C panel. There were no significant differences in breadth of responses between the groups for either subtype A or C. Neutralization breadth

and titers to subtype B reference strains was significantly higher in progressors compared to slow progressors (both  $p<0.03$ ) with increasing nAb breadth from study entry to study exit in progressors. Progressors had cross-reactive neutralizing antibodies that targeted V2 and V3. Binding affinities of non-neutralizing antibodies to HIV-specific gp120, gp41 and p24 and to activating and inhibitory Fcγ receptors (FcγRs) were similar in both groups. However, in slow progressors, CD4 T-cell counts correlated inversely with antibody binding affinity for the activating FcγRIIIa ( $p=0.005$ ).

## Conclusion

Overall, the data suggest that neither nAbs nor non-neutralizing antibodies could be directly associated with disease attenuation. However, continuous evolution of nAbs was a potential marker of disease progression.

## Author details

<sup>1</sup>University of KwaZulu-Natal, Durban, South Africa. <sup>2</sup>Jiaotong-Liverpool University, Suzhou, China, China. <sup>3</sup>Emory University, Atlanta, GA, USA. <sup>4</sup>University of Western Australia, Australia. <sup>5</sup>Ragon Institute, Boston, MA, USA. <sup>6</sup>National Institute for Communicable Diseases, Johannesburg, South Africa. <sup>7</sup>Oxford University, UK. <sup>8</sup>University of KwaZulu Natal, Durban, South Africa.

Published: 13 September 2012

doi:10.1186/1742-4690-9-S2-P75

Cite this article as: Archary et al.: Neutralizing and non-neutralizing antibody responses in HIV-1 subtype C chronically infected patients with divergent rates of disease progression. *Retrovirology* 2012 9(Suppl 2):P75.

<sup>1</sup>University of KwaZulu-Natal, Durban, South Africa  
Full list of author information is available at the end of the article